Wedbush Securities’s Arbutus Biopharma ABUS Stock Holding History

Wedbush Securities’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,000	Closed	-$20K	–	931
2020 Q2	$20K	Sell	11,000 -32,000	-74%	-$52.4K	﹤0.01%	942
2020 Q1	$43K	Buy	+43,000	New	+$116K	0.01%	829
2017 Q2	–	Sell	-18,045	Closed	-$59K	–	839
2017 Q1	$59K	Sell	18,045 -7,300	-29%	-$20.3K	0.01%	796
2016 Q4	$62K	Buy	25,345 +8,500	+50%	+$24.7K	0.01%	770
2016 Q3	$58K	Buy	16,845 +4,845	+40%	+$18.9K	0.01%	784
2016 Q2	$42K	Buy	+12,000	New	+$50.8K	0.01%	741

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wedbush Securities's ABUS Position: Q3 2020 in Review

Wedbush Securities sold out of Arbutus Biopharma (ABUS) in Q3 2020, closing a stake of 11,000 shares — an estimated $20K sold.

Wedbush Securities first reported a position in ABUS in Q2 2016 and held it in 6 quarters. The position peaked at $62K in Q4 2016. 65 funds tracked by Wall St. Rank hold ABUS as of Q3 2020.

Wedbush Securities reported no remaining Arbutus Biopharma position as of Q3 2020 after selling out during the quarter.
Wedbush Securities sold 11,000 Arbutus Biopharma shares in Q3 2020, an estimated $20K.
Wedbush Securities first reported a position in Arbutus Biopharma in Q2 2016 and held it in 6 quarters.
Wedbush Securities's Arbutus Biopharma position peaked at $62K in Q4 2016.
65 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.